Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.

She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.

Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.

Acute myeloid leukemia (AML), a blood cancer that starts in the bone marrow, accounts for almost 20,000 new cases of cancer, according to the American Cancer Society.

It is one of the most common types of leukemias in adults; however, the disease comprises only about 1% of all cancers.

There are a variety of treatment options available for patients with AML, with more clinical trials evaluating new therapies in the pipeline. In this episode of the “

 talks Cancer” podcast, we spoke with Dr. Dan Pollyea, from the University of Colorado School of Medicine, about these treatment options.

Podcasts

Acute Myeloid Leukemia

CURE’s acute myeloid leukemia page features the latest cancer news and updates on acute myeloid leukemia. Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in acute myeloid leukemia.

In this episode of the “CURE Talks Cancer” podcast, Dr. Dan Pollyea discusses the basics of AML, as well as treatment options currently available for patients. 

Understanding Treatment Options for Acute Myeloid Leukemia

Latest News